Alpelisib - Novartis Oncology
Alternative Names: Alpericive - Novartis Oncology; BYL-719; NVP-BYL-719; Piqray; VijoiceLatest Information Update: 20 Jul 2024
At a glance
- Originator Novartis
- Developer Columbia University; H. Lee Moffitt Cancer Center and Research Institute; Kura Oncology; Memorial Sloan-Kettering Cancer Center; Novartis; Novartis Oncology; Peter MacCallum Cancer Centre; University Health Network
- Class Amides; Antineoplastics; Fluorine compounds; Pyridines; Pyrrolidines; Small molecules; Thiazoles
- Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed HER2 negative breast cancer
- Registered Growth disorders
- Phase III Head and neck cancer; HER2 positive breast cancer; Triple negative breast cancer
- Phase II/III Lymphatic disorders
- Phase II Breast cancer
- Discontinued Gastric cancer; Gastrointestinal stromal tumours; Multiple myeloma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Rectal cancer; Solid tumours; Uveal melanoma
Most Recent Events
- 31 May 2024 Efficacy and adverse events data from a phase Ib/II trial in HER2-positive-breast-cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 06 Feb 2024 Novartis plans to file regulatory application for Lymphatic disorders in or after 2027 (Novartis pipeline, February 2024)
- 31 Dec 2023 Discontinued - Phase-I for Ovarian cancer (Combination therapy, Second-line therapy or greater) in Finland (PO)